Posted by Michael Wonder on 07 Jan 2020
RadioMedix and Curium announce FDA filing of copper Cu 64 dotatate injection new drug application
7 January 2020 - RadioMedix and its commercial partner Curium announced today that the new drug application for copper Cu 64 dotatate injection was filed with the U.S. FDA.
Copper Cu 64 dotatate injection is a PET diagnostic agent intended for somatostatin receptor expressing neuroendocrine tumours.
The FDA previously granted fast track designation to copper Cu 64 dotatate injection.
